Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ENOXAPARIN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Moderate to severe pain where an opioid analgesic is appropriate
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients with acute illness and restricted mobility,Inpatient treatment of acute DVT with or without pulmonary embolism (PE) when administered with warfarin,Outpatient treatment of acute DVT without PE when administered with warfarin,Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention (PCI)
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Enoxaparin is partially metabolized in the liver via desulfation and depolymerization by heparanase and other enzymes. It has a complex pharmacokinetic profile with dose-dependent clearance; renal excretion accounts for elimination of active fragments and the unchanged drug.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
80% bound to antithrombin III (low affinity to other plasma proteins).
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
0.04-0.06 L/kg (plasma volume distribution; low Vd indicates limited extravascular distribution).
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Subcutaneous: 90-92% (complete absorption).
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Cr Cl < 30 m L/min: reduce dose to 1 mg/kg subcutaneous once daily
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to increased bleeding risk
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Neonates and infants: 1.5 mg/kg subcutaneous every 12 hours; Children < 2 months: 1.5 mg/kg every 12 hours; Children ≥ 2 months: 1 mg/kg every 12 hours
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
Increased risk of bleeding; consider lower doses (e.g., 0.5 mg/kg every 12 hours or 1 mg/kg once daily) and monitor renal function
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
Enoxaparin carries a black box warning for the risk of spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis. Patients should be monitored for signs of neurological impairment, and concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants) increases the risk.
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Spinal/epidural hematoma risk with neuraxial anesthesia,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or age >65,Heparin-induced thrombocytopenia (HIT) risk; monitor platelet counts regularly,Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min), as enoxaparin accumulates and increases bleeding risk; dose adjustment required,Not recommended in patients with mechanical heart valves, especially pregnant women, due to risk of valve thrombosis,Do not mix with other injections or infusions
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Active major bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenic purpura),History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT),Hypersensitivity to enoxaparin, heparin, or pork products,Not recommended for use in patients with mechanical heart valves (especially pregnant women) due to risk of valve thrombosis,Concomitant use of other drugs that significantly increase bleeding risk (e.g., warfarin, aspirin, clopidogrel) without careful monitoring and indication
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
No specific food interactions. However, foods high in vitamin K (e.g., leafy greens) may theoretically affect coagulation but are not clinically significant with enoxaparin. Avoid excessive alcohol intake due to potential bleeding risk. Maintain consistent diet if also taking warfarin.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requires careful monitoring for bleeding.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Excretion into breast milk is minimal; M/P ratio not determined. Considered compatible with breastfeeding; no known adverse effects in nursing infants, but monitor for bleeding signs.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
Pregnancy increases volume of distribution and clearance of enoxaparin, necessitating dose adjustment. Monitor anti-Xa levels and adjust dose to maintain target levels, typically requiring higher doses per weight in late pregnancy.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-Xa levels in patients with renal impairment (Cr Cl <30 m L/min), obesity, or pregnancy. Avoid intramuscular injections and use with caution in patients receiving neuraxial anesthesia due to risk of spinal hematoma. Protamine sulfate partially reverses enoxaparin (up to 60% of anti-Xa activity). Does not routinely require monitoring of a PTT.
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
Inject subcutaneously as directed, rotating injection sites (e.g., left/right abdomen, alternating).,Do not massage the injection site after administration.,Report any signs of bleeding: unusual bruising, prolonged bleeding from cuts, blood in urine or stool, coughing up blood.,Seek immediate medical attention for symptoms of spinal hematoma after neuraxial procedure: back pain, numbness or weakness in legs, bowel/bladder dysfunction.,Inform all healthcare providers (including dentists) that you are taking enoxaparin.,Avoid NSAIDs, aspirin, or other blood thinners unless prescribed by your doctor.
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE vs ENOXAPARIN SODIUM, answered by our medical review team.
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. ENOXAPARIN SODIUM is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ENOXAPARIN SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. The standard adult dose of ENOXAPARIN SODIUM is: 1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE and ENOXAPARIN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. ENOXAPARIN SODIUM is classified as Category A/B. Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.